OncoSec Medical Incorporated · OTC:ONCSQ

OncoSec Medical — Investor Presentation (February 2021)

40 slides from OncoSec Medical's investor presentation, February 2021

  1. Slide 1: Powerful, Tumor-agnostic Immunotherapy Treatment

    Powerful, Tumor-agnostic Immunotherapy Treatment ONCOSEC’S PLATFORM TO ATTACK VISCERAL, CUTANEOUS AND SUBCUTANEOUS TUMORS NASDAQ: ONCS FEBRUARY 2021

  2. Slide 2: Forward Looking Statements

    FORWARD LOOKING STATEMENTS To the extent statements contained in the following retain key scientific or management personnel; (viii) presentations are not descriptions of historical facts the anticipated timing of clinical data availability; (ix) regarding OncoSec Medical Incorporated, they should t

  3. Slide 3: Investment Highlights

    Ticker: NASDAQ: ONCS Investment Highlights Market Cap (as of 2/20/21): ~$245M Stock Price (as of 2/20/21): $6.85 • Late-stage biotechnology company focused on intratumoral (IT) delivery of DNA-based immunotherapies as monotherapy and in combination regimes • Developing treatments for solid tumor can

  4. Slide 4: The Promise of Immunotherapy Has Yet to Be Fully Realized

    How Checkpoint Inhibitors Work The Promise of Molecular switches known as Immunotherapy Has Yet 1 checkpoints normally prevent T- cells from attacking healthy tissue to Be Fully Realized When these checkpoints, such as 2 PD-1 and PD-L1, are hijacked by cancer cells, the immune system’s T-cell respon

  5. Slide 5: Checkpoint Non-response in 60-90% of Cases

    Checkpoint Powerful drugs (like KEYTRUDA®) have been highly Non-response successful for some patients, but not the majority in 60-90% 90% of cancers are solid tumors. Of these: of Cases % OF CHECKPOINT TUMOR TYPE NON-RESPONDERS MELANOMA ˜60-80% ~30% ~70% Hot Tumors Cold Tumors TRIPLE NEGATIVE BREAST

  6. Slide 6: TAVO is Capable of Reversing Resistance to Checkpoint Therapies

    TAVO (plasmid-based interleukin-12) is administered locally at the tumor site using OncoSec’s electroporation gene TAVO™ is Capable of delivery system. TAVO is designed to induce local expression of IL-12, turning “cold” tumors “hot” and Reversing Resistance enabling checkpoint therapies to be effec

  7. Slide 7: IL-12 Is a Key Mediator of Communication Between Immune Cells

    IL-12 IS A KEY MEDIATOR OF COMMUNICATION BETWEEN DC/MACROPHAGES (INNATE) & EFFECTOR T CELLS AND NK CELLS (ADAPTIVE) Lasek W, et al, Cancer Immunol Immunother 2014

  8. Slide 8: Gene Electro Transfer of Immunotherapy: An Intratumoral IL-12 Factory

    Gene Electro Transfer of Immunotherapy: An Intratumoral IL-12 Factory The IL-12 Factory DNA plasmid IL-12 is injected into the IL-12/IFN𝛾 Feed Forward Loop tumor, followed by Tumors express IL-12 a 3 sec. pulse of stimulating NK and T energy cells to make IFN-𝛾, which then feeds Tumor cells take…

  9. Slide 9: Benefits of Electro Gene Transfer System

    Benefits of Electro Gene Transfer System A non-invasive, Rapid Transfection Versatile More rapid than Wide array of molecules can non-chemical, non- traditional chemical or be transfected, and can be toxic method that biologic cell transfection applied to a broad selection techniques of cell types i

  10. Slide 10: Seamless Delivery Of Plasmid IL-12

    Seamless Generator • Fixed electrical field intensity Delivery Of • Momentary electrical pulses (100 µsec duration and 300 Plasmid IL-12 millisecond interval) • Pulses activated by foot switch + Energy • 16 lbs. 12.5” w x 5.5” h x 13” d Step 3: Electroporation Electrical pulses, activated by a foot

  11. Slide 11: TAVO: A Tumor Agnostic Platform with Single Agent Activity

    5 TAVO: A Tumor Agnostic CLINICAL/ IMMUNOLOGICAL SIGNAL IN FIVE TUMOR TYPES Platform with Single Agent Activity TAVO + PEMBRO COMBINATION TAVO SINGLE AGENT SPONSORED TRIALS INVESTIGATOR-SPONSORED TRIALS Metastatic Melanoma Metastatic TNBC U.S. Orphan Accelerated Approval Metastatic Metastatic Fast T

  12. Slide 12: Clinical Pipeline is Well Diversified with Multiple Growth Opportunities

    Clinical Pipeline is Well Diversified with Multiple Growth Opportunities REGIMEN TRIAL INDICATION N PARTNER PHASE 1 PHASE 2 PIVOTAL TAVO + Checkpoint Resistant KEYNOTE-695 ~100 pembrolizumab Metastatic Melanoma TAVO + Triple Negative Breast KEYNOTE-890 ~65 pembrolizumab Cancer (TNBC) TAVO + CORVax12

  13. Slide 13: FDA Fast Track KEYNOTE-695

    FDA Fast Track KEYNOTE-695 Ongoing pivotal trial in PD-1 checkpoint resistant metastatic melanoma provides a pathway towards accelerated approval GRANTED FAST TRACK AND ORPHAN DRUG DESIGNATIONS Fast-track makes Program for patients Must meet TAVO™ eligible for with no FDA RECIST (tumor accelerated a

  14. Slide 14: KEYNOTE-695 Trial Design and Eligibility

    Up To Number Of 30 Sites PATIENTS TO BE TREATED 100 Canada Italy United States Australia DEFINITIVE CLINICAL PROGRESSION ON FULL COURSE ANTI-PD-1 Stage 3/4 No intervening Received at Progressive Documented Eligible Melanoma therapies permitted patient/definitive least 12 weeks + disease + disease +

  15. Slide 15: Patient Demographics and Disease Characteristics

    Patient Demographics and Disease Characteristics ‡Based on maximum value prior to dosing; # 2 patients with ≥ 2X ULN Fernandez-Peñas, P. et al., SITC Annual Meeting 2020, data as of September, 2020 15

  16. Slide 16: 5 of 54 Evaluable Patients had 100% Tumor Reduction

    Investigator-Assessed Response per Recist v1.1 – Preliminary Data 5 of 54 Evaluable Patients had 100% Tumor Reduction Fernandez-Peñas, P. et al., SITC Annual Meeting 2020 data as of September, 2020 16

  17. Slide 17: Treatment-Related Adverse Events (TRAE) in ≥ 5% of Patients

    Treatment–Related Adverse Events (TRAE) in ≥ 5% of Patients All Grades n(%) (N=56) Grade 1/2 Grade 3 Grade 4 Grade 5 Patients with at least one TEAE 43 (76.8%) 40 (71.4%) 3 (5.4%) - - Fatigue 15 (26.8%) 15 (26.8%) - - - Procedural pain 13 (23.2%) 13 (23.2%) - - - Diarrhea 11 (19.6%) 11 (19.6%) - - -

  18. Slide 18: Treated and Untreated Lesions from Responding Patients

    Treated and Untreated Lesions from 16 Responding Patients Fernandez-Peñas, P. et al., SITC Annual Meeting 2020, data as of September, 2020 18

  19. Slide 19: Actively Progressing Patients & Short Interval Between Last Anti-PD-1 Dose and Study Treatment

    Actively Progressing Patients & Short Interval Between the Last Dose of Anti-PD-1 and Study Treatment Fernandez-Peñas, P. et al., SITC Annual Meeting 2020, 19 Data as of September, 2020

  20. Slide 20: Actively Growing Lesions Significantly Reduced in Size after pIL-12 + Pembrolizumab

    Actively Growing Lesions Significantly Reduced in Size after pIL-12 + Pembrolizumab Treatment Fernandez-Peñas, P. et al., SITC Annual Meeting 2020, data as of September, 2020 20

  21. Slide 21: Pseudo Progression in Target Lesion followed by Tumor Response

    Pseudo Progression in Target Lesion followed by tumor Response [Stage IVB; PR (-93%)] Fernandez-Peñas, P. et al., SITC Annual Meeting 2020, data as of September, 2020 21

  22. Slide 22: Progression on Ipi/Nivo Followed by Tumor Response

    Progression on Ipi/Nivo Followed by Tumor Response[Stage IVC; PR (-53%)] Fernandez-Peñas, P. et al., SITC Annual Meeting 2020, data as of September, 2020 22

  23. Slide 23: US Market Opportunity in Metastatic Melanoma

    US Market Focusing First on Metastatic Melanoma Opportunity in the United States 91,000 diagnosis 9,000 deaths each year each year 90% of all cancer cases are solid tumors Incidence of melanoma US melanoma market on the projected to almost 1.6M new cases of solid tumors in the US rise (1.4% yearly f

  24. Slide 24: Commercialization by 2022 Targeted

    Commercialization by 2022 Targeted 2021 2022 Pre-BLA Meeting FDA Accelerated Approval of TAVO with FDA for Metastatic Melanoma Potential US TAVO is US Orphan Designated and Keynote-695 is fast Regulatory 2021/22 tracked. OncoSec will seek Timeline Submission of BLA for accelerated approval Accelerat

  25. Slide 25: Expanding KEYNOTE-890 into First-Line mTNBC

    Expanding KEYNOTE-890 into First-Line mTNBC Primary Endpoint: ORR by blinded independent central PHASE 2 COHORT 1 COHORT 2 review (BICR) based on RECIST v1.1 Multi-cohort, open-label study TAVO and KEYTRUDA TAVO and KEYTRUDA plus of TAVO in combination with in patients with heavily Chemotherapy in p

  26. Slide 26: Case #1: TNBC BOR: CR (-100.0%)

    CASE #1: TNBC BOR: CR (-100.0%) Total # Baseline Max tumor Age Sex Metastasis Prior Rx EOT of priors SLD (mm) reduction 35 F Liver, skin, LN 3 Paclitaxel; dox + cyclopho + goserelin; capecitabine 84.5 -100 Ongoing LDH at 1 non target skin nodule was treated with PD-L1 IL-12 EP. Three liver target le

  27. Slide 27: Case #2: TNBC BOR: PR (-67.0%)

    CASE #2: TNBC BOR: PR (-67.0%) Total # Baseline Max Tumor Age Sex Metastasis Prior Rx EOT of priors SLD (mm) reduction Breast, lung, lymph Paclitaxel: capecitabine: eribulin; 46 F 5 116 -67 Ongoing node cyclo + dox: carbo + gem LDH at PD-L1 Baseline Baseline C9D1 251 Negative Partial response 25 Com

  28. Slide 28: Recent Peer Reviewed Publications

    Recent Peer Reviewed Publications *Click thumbnails to access full articles TAVO + PEMBRO IN ANTICIPATED TAVO SINGLE AGENT ABSCOPAL EFFECT ANTI-PD-1 CHECKPOINT FAILURES 28

  29. Slide 29: Future Opportunities: TAVO is Tumor Agnostic

    FUTURE OPPORTUNITIES TAVO™ is Tumor Agnostic Renal Cell Ovarian Head/Neck Carcinoma Triple Negative Bladder Colorectal Giving life to the promise of Pancreatic Breast immunotherapies across cancer types HI Few cancers are highly infiltrated or “HOT” - most LYMPHOCYTES fall on a spectrum from warm (c

  30. Slide 30: The Power of TAVO for Visceral Lesions (liver, GI, lung)

    The Power of TAVO™ INTRODUCING THE for Visceral Lesions VLA: Visceral Lesion Applicator (liver, GI, lung) Pioneering technology Flexible catheter- Rigid trocar-based designed to target and based applicator applicator treat tumors located deep inside the body Lower voltage Apollo generator to be used

  31. Slide 31: VLA Highlights

    VLA Highlights 1 Rigid and catheter models: Used with bronchoscope, cystoscope, and trocar 2 Prototype successfully tested in large animal model: bone, pancreas, liver, lung, & bladder NEEDLE/ELECTRODES EXPANDED ENTERS THE ORGAN DRUG DELIVERY GENE ELECTROTRANSFER 1 2 3 31

  32. Slide 32: OncoSec Catheter VLA

    ONCOSEC CATHETER VLA VISCERAL LESION APPLICATOR A P P L I C A B L E I N D I C AT I O N S Lung Bladder GI Tract BRONCHOSCOPE CYSTOSCOPE ENDOSCOPE A P P L I C ATO R M E A S U R E M E N T S Electrode Width Electrode Length Injection Needle 4.5mm (+/- 0.5mm) 8mm (+/- 0.5mm) 4mm (+/- 1mm) May reduce leng

  33. Slide 33: OncoSec Rigid VLA

    ONCOSEC RIGID VLA A P P L I C A B L E I N D I C AT I O N S VISCERAL LESION APPLICATOR Liver Bone Pancreas A P P L I C ATO R M E A S U R E M E N T S Electrode Width Electrode Length Injection Needle 4.5mm (+/- 0.5mm) 8mm (+/- 0.5mm) 4mm (+/- 1mm) May reduce length depending on application 4.5mm LIVER

  34. Slide 34: CORVax12 Vaccine for COVID-19

    CORVax12 Vaccine for COVID-19 CORVax12 is a DNA vaccine The combination of IL-12 and Providence Cancer Institute is which combines OncoSec’s NIH’s spike protein is designed conducting a Phase I trial of TAVO / IL-12 immunotherapy IN to drive a coordinated vaccine CORVax12 with NIH’s “spike” protein

  35. Slide 35: Leveraging World Class Strategic Partnerships to Enhance Pipeline Value

    Leveraging World Class Strategic Partnerships to Enhance Pipeline Value We are partnering with Merck Emerge collaboration provides Our partnership with CGP gives Through our partnership with on several KEYNOTE clinical Australian metastatic us the ability to develop and Sirtex, we have access to top

  36. Slide 36: Strong Financial Position to Drive TAVO Development Forward

    Strong Financial Position to Drive TAVO™ Development Forward ~$24M ~36M Total Shares Outstanding Cash & Equivalent as of as of Feb 2021 10/31/20 ~$42M Financing Completed Jan 2021 36 36

  37. Slide 37: Anticipated Milestones

    Anticipated Milestones Closed on $42 million financing Obtain IND for CORVax12, a vaccine for COVID-19 Provide interim data update at SITC 2020 for KEYNOTE-695 Complete enrollment in registration directed KEYNOTE-695 study First patient dosed KEYNOTE-890 Cohort 2 first line mTNBC First patient dosed

  38. Slide 38: Established Biotech Leaders

    Established Biotech Leaders BOARD OF DIRECTORS WITH A TRACK RECORD OF SUCCESS Daniel J. O’Connor, JD Chief Executive Officer & Director MANAGEMENT Margaret R. Dalesandro, Ph.D. Chair Daniel J. O’Connor Robert W. Ashworth, Ph.D Herbert Kim Lyerly, M.D. President/Director/CEO Senior Vice President Dir

  39. Slide 39: OncoSec is Positioned for Success with TAVO

    OncoSec is Positive tumor Well tolerated, natural Positioned shrinkage/response data being generated by our lead product solution that may increase the efficacy of checkpoint for Success with candidate, TAVO, across multiple solid tumor types therapies TAVO™ Expanding device Fast Track and US Orphan

  40. Slide 40: Thank You

    Thank You Brian Leuthner CHIEF OPRERATING OFFICER 908.531.4566 baleuthner@oncosec.com HEADQUARTERS SCIENTIFIC LAB & RESEARCH 24 NORTH MAIN STREET 3565 GENERAL ATOMICS CT. PENNINGTON, NJ SAN DIEGO, CA

OncoSec Medical — Investor Presentation (February 2021) on 6ix